ArticleFrontiers in oncology2025
Integrative multi-omics stratification and translational evaluation of Treg-targeted combination immunotherapy in breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulatory T cells in breast cancer drivers of immune suppression and targets for immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunosuppressive breast cancer subtypes driven by regulatory T cells (Tregs) remain under-characterized, limiting precise identification of patients who may benefit from immunomodulatory therapies. Tregs are key mediators of immunosuppression within the tumor microenvironment (TME) and are closely associated with resistance to immune checkpoint inhibitors (ICIs). Therefore, defining and characterizing tumors with predominant Treg-mediated immunosuppression is essential for optimizing the use of Treg-targeted and combination immunotherapies. Methods: We applied an unsupervised multi-omics integration approach across four molecular layers - mRNA, miRNA, DNA methylation, and proteomics -to identify immunologically distinct subtypes of breast cancer. Autoencoder-based dimensionality reduction followed by consensus clustering revealed a subgroup characterized by high Treg infiltration and immunosuppressive signaling, referred to as the Treg-enriched subtype. To evaluate therapeutic strategies, we employed a spatial quantitative systems pharmacology (spQSP) model simulating tumor-immune dynamics and tested Treg-targeted and PD-1 blockade therapies both alone and in combination. Results: The C2 cluster exhibited elevated Treg-related signatures and a highly immunosuppressive tumor microenvironment. A similar Treg-enriched cluster was also identified in an independent cohort, supporting the robustness and clinical relevance of this immunosuppressive subtype. In-silico simulations performed under a C2-like, immunosuppressive context predicted that combining Treg-targeted therapy with PD-1 blockade would substantially enhance immune activation and tumor control compared with monotherapy. To experimentally validate these predictions, combination treatment of a CCR8 inhibitor (IPG7236) and anti-PD-L1 antibody demonstrated greater tumor growth inhibition than either monotherapy in the EMT6 model, confirming the predicted therapeutic synergy in Treg-enriched, immune-suppressive tumors. Conclusion: This study identifies Treg-enriched and immunosuppressive breast cancer subtype through integrative multi-omics analysis and demonstrates, through both in-silico and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.